AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NIH cancels contract for HIV vaccine program.
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- NOVAVAX, INC. (NASDAQ:NVAX) announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has cancelled its 5-year contract [NO1-AI-30042] for the development of human immunodeficiency virus (HIV) vaccine candidates due to programmatic considerations for "the government's convenience."
Novavax had been the prime contractor, with Emory University, Tulane University, and the University of Pittsburgh as subcontractors.
This event is not expected to have a material financial impact on Novavax. The company expects to recover costs incurred to date in association with this contract. Novavax has a second HIV vaccine program funded by the U.S. National Institutes of Health through a consortium led by the University of Alabama at Birmingham and including Emory University and Harvard University. This second NIH-funded HIV vaccine program is not impacted by this event.
Dr. Gale E. Smith, vice president, vaccine development commented, "Our HIV vaccine development program will now focus on the contract with the University of Alabama. HIV ...
- NIH intended for development of oral prophylactic/therapeutic HIV...
- Newspaper article from: Vaccine Weekly November 6, 2002 700+ words
...announced that they have received a 2-year $600,000 National Institutes of Health (NIH) SBIR Grant to develop an oral form of...patient, clinical trial of an autologous, therapeutic HIV vaccine sponsored by BioDelivery. The delivery vehicles to be used...
- Quest for the HIV vaccine.(National Institutes of Allergy and Infectious...
- Magazine article from: Popular Science July 1, 2001 700+ words
...future? To find out, POPULAR SCIENCE spoke with Gary Nabel, director of the Vaccine Research Center at the National Institutes of Allergy and Infectious Disease. What has been the main challenge? Nabel: The virus is genetically diverse...
- Epimmune's HIV Vaccine Candidate Taken by the National Institutes of Health and...
- Press release article from: PR Newswire April 7, 2003 700+ words
...Diseases, a component of the National Institutes of Health (NIH), holds...recently initiated by the HIV Vaccine Trials Network (HVTN...ideal setting to evaluate our HIV vaccine candidate." "The HVTN...speeding progress toward an HIV vaccine and controlling the global...
- Epimmune Awarded $16.7 Million National Institutes of Health Contract For HIV...
- Press release article from: PR Newswire September 29, 2003 700+ words
...Infectious Diseases (NIAID) at the National Institutes of Health (NIH), an agency...evaluation by the NIAID-sponsored HIV Vaccine Trials Network (HVTN). The award was made under the NIAID's HIV Vaccine Design and Development Teams...
- GenVec and the National Institutes of Health (NIH) Expand Manufacturing...
- Press release article from: PR Newswire January 6, 2004 700+ words
...Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The latest expansion...expansion, GenVec will manufacture the HIV vaccine candidate, based on its proprietary...their confidence in GenVec to produce HIV vaccine clinical materials to support late...
- Crucell and the US National Institutes of Health Sign Contract for Production...
- Press release article from: PR Newswire October 14, 2002 700+ words
...Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The NIH is the primary...Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and...
- GeoVax Merger Gains $13M To Help HIV Vaccine Effort.(Editorial)
- Magazine article from: BIOWORLD Today Osborne, Randall January 26, 2006 700+ words
...as possible GeoVax's HIV vaccine, which deploys a two...cells. In 2004, the HIV Vaccine Trials Network, sponsored by the National Institutes of Health in Bethesda...equity financing, and its HIV vaccine programs have garnered...
- VAXGEN'S HIV VACCINE FIRST IN PHASE III TO PREVENT AIDS By Lisa Seachrist...
- Magazine article from: BIOWORLD Today June 4, 1998 700+ words
...trial is a significant turnaround in HIV vaccine development. In June 1994, the National Institutes of Health (NIH) decided to shelve...Carlsbad, Calif., currently has an HIV vaccine, Remune, in a three-year Phase III...